- Home
- OPP vs ACHV Comparison
OPP vs ACHV Comparison
Compare OPP & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPP
- ACHV
- Stock Information
- Founded
- OPP 2010
- ACHV N/A
- Country
- OPP United States
- ACHV United States
- Employees
- OPP N/A
- ACHV N/A
- Industry
- OPP Finance/Investors Services
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- OPP Finance
- ACHV Health Care
- Exchange
- OPP Nasdaq
- ACHV Nasdaq
- Market Cap
- OPP 204.0M
- ACHV 167.6M
- IPO Year
- OPP N/A
- ACHV N/A
- Fundamental
- Price
- OPP $8.27
- ACHV $4.20
- Analyst Decision
- OPP
- ACHV Strong Buy
- Analyst Count
- OPP 0
- ACHV 1
- Target Price
- OPP N/A
- ACHV $12.00
- AVG Volume (30 Days)
- OPP 108.0K
- ACHV 1.6M
- Earning Date
- OPP 01-01-0001
- ACHV 11-06-2025
- Dividend Yield
- OPP 14.41%
- ACHV N/A
- EPS Growth
- OPP N/A
- ACHV N/A
- EPS
- OPP N/A
- ACHV N/A
- Revenue
- OPP N/A
- ACHV N/A
- Revenue This Year
- OPP N/A
- ACHV N/A
- Revenue Next Year
- OPP N/A
- ACHV N/A
- P/E Ratio
- OPP N/A
- ACHV N/A
- Revenue Growth
- OPP N/A
- ACHV N/A
- 52 Week Low
- OPP $7.26
- ACHV $1.84
- 52 Week High
- OPP $8.83
- ACHV $5.31
- Technical
- Relative Strength Index (RSI)
- OPP 37.88
- ACHV 74.99
- Support Level
- OPP $8.22
- ACHV $3.06
- Resistance Level
- OPP $8.42
- ACHV $3.48
- Average True Range (ATR)
- OPP 0.10
- ACHV 0.20
- MACD
- OPP -0.02
- ACHV 0.04
- Stochastic Oscillator
- OPP 31.58
- ACHV 79.94
About OPP RiverNorth/DoubleLine Strategic Opportunity Fund Inc.
RiverNorth/DoubleLine Strategic Opportunity Fund Inc is a closed-end management investment company. The company's investment objective is to seek current income and overall total return.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.